PINOCCHIO (multiple types of cancer)
Clinical study in children on the metabolism, distribution and excretion of chemotherapy and kinase inhibitors in the body (pharmacokinetics).
Recruiting
Who can enter
Children receiving chemotherapy or kinase inhibitors (KIs) as standard of care
Age ≤18 years
Goal
Goal
In the PINOCCHIO study we investigate to what extent a young child's body handles chemotherapy or kinase inhibitors (KIs) differently than an adult or an older child's body. We do so by measuring the concentration of the drug in the blood. This allows us to find out if the dose needs to be adjusted for children.
In stratum I (the chemotherapy stratum of the study), we look at commonly used chemotherapy agents: carboplatin, cisplatin, cytarabine, dactinomycin, daunorubicin, doxorubicin, etoposide, methotrexate, and vincristine.
Stratum II (the kinase inhibitor stratum of the study) is about different classes of KIs (ALK, BCR-ABL, RAS-pathway, VEGF-R, BCL2, mTOR, FLT3 and NTRK inhibitors, and multi kinase inhibitors).
Background
Background
Most of the information on the pharmacokinetics of chemotherapeutic agents and KIs is based on research in adults. This information is also used for children, without knowing whether this is correct for this patient group.
A child's body is in full development during the first years of life. As a result, the metabolism, distribution, and excretion of the chemotherapeutic agent or KI in the body, also known as pharmacokinetics, may be different. The lack of information about how a child’s body processes these drugs may lead to overdosing or underdosing, resulting in higher risk for side effects or less effectiveness of the treatment. With this study we want to look at the differences in pharmacokinetics between adults and children of different ages, in order to find out whether the treatment dosage should be adapted for children.
Children participating in this study will have extra blood samples taken at several times after the administration of chemotherapy or KI. No changes will be made to the chemotherapy or KI treatment when a child participates in this study.
In order to participate in a study please refer to your/your child’s doctor.
Last reviewed
Last reviewed
June 5, 2026
Study details
- Study details
Official title
PINOCCHIO-study: Pharmacokinetics of anti-cancer drugs in pediatric oncologyCancer type
All types of cancer that require standard of care with chemotherapy (carboplatin, cisplatin, cytarabine, dactinomycin, daunorubicin, doxorubicin, etoposide, methotrexate and/or vincristine) or KIs (ALK, BCR-ABL, RAS-pathway, VEGF-R, BCL2, mTOR, multi-kinase, FLT3, and NTRK inhibitors)Type of study
Prospective observational studyMaximum number of patients
For stratum I, we aim to collect data from approximately 10 infants (0-12 months), 10 children (1-11 years) and 10 adolescents (12-17 years) for each chemotherapeutic agent. For stratum II we expect to collect data from approximately 10 to 20 patients per agent.Start date
Stratum I opened on 27-02-2019
Stratum II opened on 15-11-2022Status
Stratum I and II are both open for inclusionLocal Principal Investigator
Prof. dr. C.M. ZwaanSponsor
Princess Máxima Center for pediatric oncologyApproval
This study has been reviewed by an accredited medical research ethics committee. This committee has decided that it is justified to ask patients to participate in this study. More information can be found at: CCMO.Trial registry number
NL63037.078.18, NTR: NL7527
The above information is intended as a brief summary only and may not reflect the most up-to-date information. For full details and the current status of a protocol, physicians can contact the Princess Máxima Center directly.